How Likely Is Reinfection Following Covid Recovery?

Based upon what we have observed/seen/witnessed about waining vaccine effectiveness , break through infection with new variants, and new mutant variants, mRNA vaccine solutions are temporary, short term reactive solutions to mitigate viral/pathogenic infection.

Should scientists redefine the viral infection problem to include mutation in order to develop proactive, long-term effective solutions which prevent viral infection and mutation?

Is it only the unvaccinated that cause viral mutation?

Virologists identified a continuous genetic variation in Influenza viruses, not present in other viral families such as Rhabdovirus or Coronavirus, that causes an antigenic drift resulting in the variation in the viral surface antigens; this antigenic variation is responsible for the flu virus evading the immunity caused by vaccination with the previous year pathogenic strain, hence requiring an effective vaccine to be updated annually.

( Sound familiar? CV19 – annual
Booster shots?)

Although scientist have renewed their efforts to attain an “universal influenza vaccine”, this matter still remains a challenge (Wiersma et al. 2015; Barberis et al. 2016).

According to Barberis and colleagues “current research priorities include the development of a universal influenza vaccine that could offer protection against all influenza virus strains, thereby overcoming the challenges faced due to antigenic drift and shift or of co-circulation of different viral strains”.

Already in (1973), Kendal and Kiley published an article on the antigenic divergence between the neuraminidases of Asian and Hong Kong influenza viruses, and associated this divergence to short changes in the primary structure of the neuraminidase; but the full complexity of this matter did not become apparent until it was discovered that influenza viruses of different origin could recombine to either originate completely new viral strains (Desselberger et al. 1978), or at least increase their genetic variation (Young and Palese 1979).”

Are Omicron and IHU – examples of recombinate viruses of different origins to create new viral strains or increase genetic variation?

Long-term Solution:
Inhibit the viral proteins using protease/enzyme inhibitors to eliminate viral infection, mutation, need for annual vaccines, injection of viral
Proteins/prions and cytokine Storm , and prevent ADE , inflammatory /immunosuppressive diseases, and most cancers.

Do mutants evolve in an effort to escape vaccine immunization, and if so, how do they do this, and is it only in unvaccinated individuals?

Examples: how do bacteria evade antibiotic protection unless the mutating bacteria are previously exposed to the antibiotics in inoculated patients ?

How do cancers adapt to anti cancer drugs without previous exposure to anti cancer drugs in cancer patients?

Is herd immunity a hypothetical concept or a reality? Has it ever been proven? If so, where is the sensed evidence?

Or do these pathogens learn to live symbiotically with the host and, as a result , enable both host and pathogen to coexist /survive?

How many mRNA vaccines and spike proteins can our body’s immune system tolerate before it loses its innate immunity towards all foreign proteins and becomes antibody dependent resistant to only the initial viral spike protein and fails to recognize /neutralize mutant spikes or other pathogen proteins , similar to super bacteria become resistant to antibiotics?

Is our future immune protection limited to development of antibody producing vaccines and/or antibiotics because scientists are overlooking/failing to include mutation in the initial problem statement?

Logically, viruses are mainly proteins and other biological or manmade sources of protein/enzymes can be utilized to inhibit viral proteins.

Pfizer’s Paxlovid is a man made, synthesized drug which inhibits /blocks an essential viral Mpro enzyme from making viral proteins thus preventing further viral infection.

There are naturally occurring plant/fungal and other biological enzyme inhibitors sources which can also inhibit viral proteins.
Both natural and synthetic protease inhibitor solutions can be used either proactively as prophylaxis to prevent viral infection and mutation or reactively to mitigate viral infection after it occurs.

The choice for me: The Best Defense is a Proactive Offense : utilize either or both sources Prophylactically to Prevent both infection and mutation and eliminate concerns over waining vaccine effectiveness , and need for creating continuous vaccines and vaccine boosters.

Published by enoch2345

Retired Biochemist with over 40 years of problem solving experience in oil, environmental, and toxicology.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: